Goldman Scarlato & Karon Investigates Stec

Goldman Scarlato & Karon, P.C. (GSK) commenced an investigation into the August 5, 2009 secondary offering of shares by STEC, Inc. for $31.00 per share.

The investigation is to determine whether STEC violated the federal securities laws by making false and misleading statements in documents filed with the U.S. Securities and Exchange Commission in connection with its August 5, 2009 secondary offering.